Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Taurine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | GMNN | O75496 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | THPO | P40225 | 1/20 | 0.68 |
| ▸ | HBB | P68871 | 1/20 | 0.68 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.68 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | BBOX1 | O75936 | 3/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Taurine SCHEMBL29400164 | 1.00 | ALDH1A1 (0.68) | ALDH1A1LMNATSHRGMNNTP53 | |
| Taurine SCHEMBL923630 | 1.00 | — | — | |
| Taurine SCHEMBL10626131 | 0.93 | LMNA (0.60) | ALDH1A1LMNATSHRGMNNTP53 | |
| Taurine SCHEMBL688315 | 0.93 | — | — | |
| Taurine SCHEMBL29475753 | 0.93 | LMNA (0.60) | ALDH1A1LMNATSHRGMNNTP53 | |
| Taurine SCHEMBL1100955 | 0.93 | — | — | |
| Taurine SCHEMBL2288742 | 0.93 | LMNA (0.60) | ALDH1A1LMNATSHRGMNNTP53 | |
| Taurine SCHEMBL7107906 | 0.93 | LMNA (0.60) | ALDH1A1LMNATSHRGMNNTP53 | |
| Taurine SCHEMBL10952592 | 0.93 | — | — | |
| Taurine SCHEMBL30097994 | 0.93 | LMNA (0.60) | ALDH1A1LMNATSHRGMNNTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11891355-B2 | Method for preparing taurine and method for recovering mother liquor thereof | ZHEJIANG NHU COMPANY LTD. (CN) | 2024-02-06 | — | — | US | claimed |
| US-11845714-B2 | Process for producing taurine | VITAWORKS IP, LLC (US) | 2023-12-19 | — | — | US | claimed |
| WO-2026087586-A1 | METHOD FOR THE CONTINUOUS MANUFACTURE OF TAURINE | ARXADA AG (CH) | 2026-04-30 | — | — | WO | disclosed |
| US-20250051271-A1 | METHOD FOR PREPARING TAURINE, METHYLTAURATE AND METHYLTAURINE SIMULTANEOUSLY | QIANJIANG YONGAN PHARMACEUTICAL CO., LTD. (CN) | 2025-02-13 | — | — | US | disclosed |
| EP-4506333-A1 | METHOD FOR PREPARING TAURINE, METHYLTAURATE AND METHYLTAURINE SIMULTANEOUSLY | Qiangjiang Yongan Pharmaceutical Co., Ltd. (CN) | 2025-02-12 | — | — | EP | disclosed |
| US-20240092732-A1 | PROCESS FOR PRODUCING TAURINE | LIBRE HOLDINGS INC. | 2024-03-21 | — | — | US | disclosed |
| US-11891355-B2 | Method for preparing taurine and method for recovering mother liquor thereof | ZHEJIANG NHU COMPANY LTD. (CN) | 2024-02-06 | — | — | US | disclosed |
| US-11851395-B2 | Process for producing alkali taurinate | VITAWORKS IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-11845714-B2 | Process for producing taurine | VITAWORKS IP, LLC (US) | 2023-12-19 | — | — | US | disclosed |
| EP-3786153-B1 | METHOD AND SYSTEM FOR REMOVING IMPURITIES OUT OF TAURINE MOTHER LIQUOR AND TAURINE MOTHER LIQUOR RECOVERY | QIANGJIANG YONGAN PHARMACEUTICAL CO LTD (CN) | 2023-07-19 | — | — | EP | disclosed |
| US-20230192603-A1 | PROCESS FOR PRODUCING ALKALI TAURINATE | LIBRE HOLDINGS INC. | 2023-06-22 | — | — | US | disclosed |
| US-20220135519-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | LIBRE HOLDINGS INC. | 2022-05-05 | — | — | US | disclosed |
| CN-111116430-B | Preparation method of sodium taurate | 万华化学集团股份有限公司 | 2022-04-22 | — | — | CN | disclosed |
| EP-3808734-B1 | THE METHOD AND PRODUCTION SYSTEM FOR FULLY RECOVERING AND TREATING TAURINE MOTHER LIQUOR | QIANGJIANG YONGAN PHARMACEUTICAL CO LTD (CN) | 2022-03-30 | — | — | EP | disclosed |
| WO-2022055782-A1 | CYCLIC PROCESS FOR PRODUCING TAURINE FROM MONOETHANOLAMINE | VITAWORKS IP, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022055780-A1 | CYCLIC PROCESS FOR PRODUCING TAURINE FROM MONOETHANOLAMINE | VITAWORKS IP, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| WO-2022055781-A1 | CYCLIC PROCESS FOR PRODUCING TAURINE FROM MONOETHANOLAMINE | VITAWORKS IP, LLC (US) | 2022-03-17 | — | — | WO | disclosed |
| US-20220073453-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | LIBRE HOLDINGS INC. | 2022-03-10 | — | — | US | disclosed |
| US-20220073455-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | LIBRE HOLDINGS INC. | 2022-03-10 | — | — | US | disclosed |
| US-11254639-B1 | Cyclic process for producing taurine from monoethanolamine | VITAWORKS IP, LLC (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092732-A1 | PROCESS FOR PRODUCING TAURINE | SLC6A6, OSGEP, ABAT | ALDH1A1 591/4885LMNA 4220/4885TSHR 3692/4885 |
| US-20220135519-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | SRM, SMS, PHOSPHO1 | ALDH1A1 2265/4885LMNA 3371/4885TSHR 4592/4885 |
| US-11254639-B1 | Cyclic process for producing taurine from monoethanolamine | SRM, PHOSPHO1, SMS | ALDH1A1 2628/4885LMNA 3603/4885TSHR 4437/4885 |
| US-20220073455-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | SRM, PHOSPHO1, SMS | ALDH1A1 2628/4885LMNA 3603/4885TSHR 4437/4885 |
| US-11845714-B2 | Process for producing taurine | OAT, CA3, MAPT | ALDH1A1 1348/4885LMNA 3589/4885TSHR 3774/4885 |
| US-11851395-B2 | Process for producing alkali taurinate | OAT, CA3, MAPT | ALDH1A1 2181/4885LMNA 3170/4885TSHR 4139/4885 |
| US-20230192603-A1 | PROCESS FOR PRODUCING ALKALI TAURINATE | OAT, CA3, MAPT | ALDH1A1 2181/4885LMNA 3170/4885TSHR 4139/4885 |
| US-20220073453-A1 | Cyclic Process for Producing Taurine from Monoethanolamine | SLC6A6, SMS, SRM | ALDH1A1 2976/4885LMNA 1557/4885TSHR 3701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.